Accelerating Biometrics Results: Cloud-Based Statistical Computing Solutions

When it comes to transforming and analyzing clinical trial data, there’s a huge number of manual steps and handoffs between siloed groups making it incredibly easy to lose information through the life cycle. A few of the most common problems are found within the biometrics area which can be plagued by disjointed systems, high IT costs, extended installation timelines, and validation burdens, among other variables. These obstacles can eat away at your budget, time, and resources. Or what if you do something wrong and need to start over? There are many solutions available, but how do you know which is the best for your project?

Join experts from Instem, Chris Decker and John Leveille partner with Wayne DellaMaestra from Dermavant Sciences to dive into how users can overcome common obstacles in the biometric area using a statistical computing environment (SCE) which provides a centralized compliance, analysis, and submission solution enabled by the cloud for any size pharmaceutical company and CROs. They’ll explain and demonstrate how using a cloud-based statistical computing environment (SCE) that comes preloaded and validated with tools, applications, and licenses for your biometric team can increase efficiency by allowing users to share data, programs, and analysis results.

Register today to learn:

• An overview of a cloud-based SCE’s value and key capabilities
• A demonstration of how programmers and statisticians can leverage different tools to improve their processes
• A sneak peak of an even more powerful cloud enabled platform for managing the biometrics workflow at large pharmaceutical companies and CROs
• Q&A portion

Speakers

Wayne DellaMaestra, Senior Director, Clinical Data Programming, Dermavant Sciences

Wayne DellaMaestra is Senior Director, Clinical Data Programming at Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology.   Wayne has a Master’s degree in Computer Science and a Bachelor’s degree in Statistics with over 30 years of clinical research and drug development experience.  At Dermavant, he leads the Data Management function and regularly uses SAS software to perform quality checks on the clinical data provided by CROs.   He also works closely with the team of Dermavant statisticians and programmers who are using SAS to analyze the data and provide outputs for use in regulatory submissions and publications.  He previously held a similar position at United Therapeutics where he supported the approval of multiple products.

Message Presenter

Chris Decker, VP Clinical Solutions, Instem

Chris Decker serves as the Vice President of Clinical Solutions at Instem. He has 25+ years of experience within the clinical data lifecycle including design and implementation of clinical systems, processes and innovation. He has driven initiatives within pharmaceutical biometrics organizations solving problems and driving innovation by leveraging technology and transforming processes. Outside of Instem, Chris serves on the CDISC Board of Directors and as a member of PHUSE CSS Steering Committee. Chris brings a diverse background of knowledge and experience with an overall passion to enable innovation for a healthier world.

Message Presenter

John Leveille, Executive Vice President, Clinical Trial Acceleration, Instem

John Leveille was formerly the Co-Founder and CEO of D-wise which was acquired by Instem. He now heads up the Clinical Trial Acceleration unit as Executive Vice President. John has over 20 years of experience in software design and development. As a lead developer at SAS, he was a pioneer in connecting SAS technology with emerging Internet business models, bringing the power of analytics to web applications across a wide variety of businesses. John was awarded two software patents for innovative solutions developed while at SAS. In the early 2000’s he embarked on a consulting career, helping clients to understand and apply technology to their businesses, eventually focusing on the Life Sciences arena.

Message Presenter